小児神経芽腫治療の世界市場2023-2030

小児神経芽腫治療の世界市場は、予測期間中にCAGR 10.3％で成長すると予測されています。小児神経芽腫治療とは、小児の神経系に影響を及ぼすがんや腫瘍に対する一種の治療を指します。小児神経芽腫の新規症例数の増加は、予測期間中の小児神経芽腫治療市場の成長を促進すると予想されています。例えば、2023年3月、米国を拠点とする腫瘍学の専門家と医師のための組織である米国臨床腫瘍学会（ASCO）が発表した記事によると、神経芽腫は米国で毎年約700～800人の若者を罹患させています。米国では、神経芽細胞腫は全小児悪性腫瘍の6.0％を占めています。神経芽細胞腫は5歳未満の子供の約90.0％が罹患します。さらに、小児医療インフラを構築するための研究開発イニシアティブに対する政府の投資拡大が、市場の成長をさらに押し上げると思われます。例えば、2022年3月、調査財団は小児がん研究のために31機関の51人の研究者に340万米ドルの助成金を提供しています。

セグメント別の展望

化学療法サブセグメントが世界の小児神経芽腫治療市場で圧倒的なシェアを占めると予測される

サブセグメント成長の主な要因は、神経芽腫の治療における化学療法薬の有効性です。化学療法は、症状を軽くし、病気の広がりを抑えるために好ましい治療方法です。また、放射線療法や外科手術のような他の治療法とも併用されます。例えば、2021年6月、メモリアル・スローン・ケタリングがんセンターは、N9が神経芽腫の子供にとって安全で効率的な治療法であるかどうかを判断することに焦点を当てた臨床研究を後援しました。シクロホスファミド、トポテカン、ビンクリスチン（CTV）は、N9レジメン（CDV）を構成する3つの化学療法薬の組み合わせです。さらに、小児神経芽腫の治療における化学療法の有効性を調査するための投資が増加しており、サブセグメントの成長をさらに押し上げると思われます。例えば、2022年1月、Jason Shohet医学博士がHyundai Hope on Wheelsから2年間30万米ドルのScholar Hope Grantを受け、神経芽腫の治療における薬剤耐性の克服に注力しています。

地域別の展望

北米が世界の小児神経芽腫治療市場で大きなシェアを占めると予測される

同地域の市場成長を促進する重要な要因としては、同地域における小児神経芽腫の高い頻度、確立されたヘルスケアインフラ、新製品の承認などが挙げられます。例えば、2022年6月、FDAは神経芽腫の中枢神経系転移またはleptomeningeal転移（脳と脊髄を取り囲む脳脊髄液に転移する疾患）を有する小児の治療薬として、オンブラスチス（オンブルタマブ）に生物製剤承認申請の優先審査を認めました。

共同研究、合併、買収などを含むイニシアチブの拡大も、市場の拡大に大きく寄与すると思われます。例えば、2021年8月、米国のバイオテクノロジー企業であるユナイテッド・セラピューティクス社は、元NFL選手デボン・スティル氏とその娘リアと提携し、「Braving NeuroBLASToma」と呼ばれる教育イニシアチブを開始したと発表しました。このイニシアチブは、神経芽細胞として知られる未熟な神経細胞を侵すがんについて、人々にもっと知ってもらうことを意図しています。米国ノースカロライナ州を拠点とするイザベラ・サントス財団は、小児神経芽細胞腫に苦しむ子どもたちを支援するため、精密医療を用いた治療費1500ドルを負担しています。同財団は、2022年10月までに約81人の子どもたちを支援しており、精密医療にかかる費用が保険でカバーされるようになるまで、将来的にはさらに多くの子どもたちを支援する予定です。

目次

第1章 レポート概要

• 業界の現状分析と成長ポテンシャルの展望
• 調査方法とツール
• 市場内訳
  • セグメント別
  • 地域別

第2章 市場概要と洞察

• 調査範囲
• アナリストの洞察と現在の市場動向
  • 主な調査結果
  • 推奨事項
  • 結論

第3章 競合情勢

• 主要企業分析
• APEIRON Biologics AG
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Baxter Healthcare Corp.
  • 会社概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Cellectar Biosciences, INC.
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• United Therapeutics Corp.
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• 主要戦略分析

第4章 市場セグメンテーション

• 小児神経芽腫治療の世界市場：治療タイプ別
  • 化学療法
  • 免疫療法
  • 放射線療法
  • その他（手術療法、標的療法）
• 小児神経芽腫治療の世界市場：エンドユーザー別
  • 病院
  • 専門クリニック
  • その他（調査機関）

第5章 地域別分析

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • イタリア
  • スペイン
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 世界のその他の地域

第6章 企業プロファイル

• AstraZeneca
• Bayer AG
• Bristol-Myers Squibb Co.
• Cell Ectar Biosciences Inc.
• Clarity Pharmaceuticals
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Johnson & Johnson Services, Inc.
• MacroGenics Inc.
• Marsala Biotech Inc.
• Merck & Co.
• Pfizer Inc.
• Provectus Biopharmaceuticals Inc.
• Sartorius AG
• Sun Pharmaceuticals Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Y-mAbs Therapeutics Inc.

LIST OF TABLES

• 1. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2022-2030 ($ MILLION)
• 2. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT BY CHEMOTHERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 3. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT BY IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 4. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT BY RADIATION THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 5. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT BY OTHER TREATMENT TYPES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 6. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
• 7. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 8. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT IN SPECIALTY CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 9. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT IN OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 10. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 11. NORTH AMERICAN PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 12. NORTH AMERICAN PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2022-2030 ($ MILLION)
• 13. NORTH AMERICAN PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
• 14. EUROPEAN PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 15. EUROPEAN PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2022-2030 ($ MILLION)
• 16. EUROPEAN PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
• 17. ASIA-PACIFIC PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 18. ASIA-PACIFIC PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2022-2030 ($ MILLION)
• 19. ASIA-PACIFIC PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
• 20. REST OF THE WORLD PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 21. REST OF THE WORLD PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2022-2030 ($ MILLION)
• 22. REST OF THE WORLD PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

• 1. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SHARE BY TREATMENT TYPE, 2022 VS 2030 (%)
• 2. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT BY CHEMOTHERAPY MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 3. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT BY IMMUNOTHERAPY MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 4. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT BY RADIATION THERAPY MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 5. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT BY OTHER TREATMENT TYPES MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 6. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SHARE BY END-USER, 2022 VS 2030 (%)
• 7. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT IN HOSPITALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 8. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT IN SPECIALTY CLINICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 9. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT IN OTHER END-USERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 10. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 11. US PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
• 12. CANADA PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
• 13. UK PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
• 14. FRANCE PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
• 15. GERMANY PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
• 16. ITALY PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
• 17. SPAIN PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
• 18. REST OF EUROPE PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
• 19. INDIA PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
• 20. CHINA PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
• 21. JAPAN PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
• 22. SOUTH KOREA PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
• 23. REST OF ASIA-PACIFIC PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
• 24. REST OF THE WORLD PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)

Title: Global Pediatric Neuroblastoma Treatment Market Size, Share & Trends Analysis Report by Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy, and Others), and by End-User (Hospitals, Specialty Clinics and Others) Forecast Period (2023-2030).

The global pediatric neuroblastoma treatment market is anticipated to grow at a CAGR of 10.3% during the forecast period. Pediatric neuroblastoma treatment refers to a kind of treatment for cancer or a tumor that affects the nervous system in children. The rising number of new cases of pediatric neuroblastoma is expected to propel the growth of the pediatric neuroblastoma treatment market over the forecast period. For instance, in March 2023, according to an article published by the American Society of Clinical Oncology (ASCO), a US-based organization for oncology professionals and physicians, neuroblastoma affects approximately 700 to 800 youngsters in the US each year. In the US, neuroblastoma accounts for 6.0% of all childhood malignancies. Neuroblastoma affects around 90.0% of children under the age of five. Additionally, the government's increased investments in R&D initiatives to build pediatric medical infrastructure will further boost market growth. For instance, in March 2022, Rally Foundation provides $3.4 million in grants to 51 researchers from 31 institutions for childhood cancer research.

Segmental Outlook

The global pediatric neuroblastoma treatment market is segmented based on treatment type and end-user. Based on treatment type, the market is sub-segmented into chemotherapy, immunotherapy, radiation therapy, and others. Based on the end-user, the market is sub-segmented into hospitals, specialty clinics, and others. Among these, the hospitals sub-segment to account for a prominent market share in the global pediatric neuroblastoma treatment market. The growth is attributed to the availability of advanced treatment technologies, and multidisciplinary collaboration.

The Chemotherapy Sub-Segment is Anticipated to Hold a Prominent Share of the Global Pediatric Neuroblastoma Treatment Market

The primary factor attributed to the sub-segment growth is the effectiveness of chemotherapeutic medications in the treatment of neuroblastoma. Chemotherapy is the preferred method of treatment to lessen symptoms and decrease the spread of the disease. It is also used in conjunction with other therapies like radiation therapy or surgery. For instance, in June 2021, the Memorial Sloan Kettering Cancer Center sponsored a clinical study that focused on determining whether N9 was a secure and efficient treatment for kids with neuroblastoma. Cyclophosphamide, topotecan, and vincristine (CTV) are the three chemotherapy drug combinations that make up the N9 regimen (CDV). Additionally, the increasing investments in researching the effectiveness of chemotherapy in treating pediatric neuroblastoma will further boost the sub-segment growth. For instance, in January 2022, Jason Shohet, MD, Ph.D., received a two-year $300,000 Scholar Hope Grant from Hyundai Hope on Wheels to focus on overcoming drug resistance in treatments for neuroblastoma.

Regional Outlook

The global pediatric neuroblastoma treatment market is further segmented based on geography including North America (the US and Canada), Europe (UK, Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East and Africa, and Latin America). Among these, the Asia-Pacific region is projected to expand at a significant CAGR during the forecast period, owing to various factors such as the increasing prevalence of pediatric neuroblastoma, advancements in precision medicine, and increasing healthcare expenditure.

North America is Anticipated to Hold a Significant Share of the Global Pediatric Neuroblastoma Treatment Market

Pivotal factors driving the market growth in the region include the high frequency of pediatric neuroblastoma in the region, the well-established healthcare infrastructure, and new product approvals. For instance, in June 2022, the FDA granted Omblastys (omburtamab) a priority review for a Biologics License Application for the treatment of children with the central nervous system or leptomeningeal metastasis (a disease that spreads to the cerebrospinal fluid that surrounds the brain and spinal cord) from neuroblastoma.

The growing initiatives including collaborations, mergers, and acquisitions, among others, will also significantly contribute to the market's expansion. For instance, in August 2021, United Therapeutics, an American biotechnology company, announced that it had partnered with former NFL player Devon Still and his daughter Leah to launch the educational initiative called 'Braving NeuroBLASToma'. The initiative intended to educate people more about cancer affecting immature nerve cells known as neuroblasts. The Isabella Santos Foundation based in North Carolina, US, is helping people whose children are suffering from pediatric neuroblastoma by paying $1500.0 for their treatment using precision medicine. The foundation helped around 81 kids by October 2022 and intends to help more in the future until insurance covers the cost of precision medicine.

Market Players Outlook

The major companies serving the global pediatric neuroblastoma treatment market include: APEIRON Biologics AG, Baxter Healthcare Corp., Cellectar Biosciences, Inc., and United Therapeutics Corp. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, funding, collaborations, and new product launches to stay competitive in the market. For instance, in March 2022, Recordati S.p.A., an Italy-based pharmaceutical group, acquired EUSA Pharma (UK) Ltd. for $824.2 million. The acquisition is expected to offer Recordati a broader portfolio of pharmaceuticals for rare diseases. EUSA Pharma (UK) Ltd. is a UK-based specialty pharmaceutical company that deals in pediatric neuroblastoma treatment.

The Report Covers:

• Market value data analysis of 2022 and forecast to 2030.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global pediatric neuroblastoma treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
• 3.2. APEIRON Biologics AG
  • 3.2.1. Overview
  • 3.2.2. Financial Analysis
  • 3.2.3. SWOT Analysis
  • 3.2.4. Recent Developments
• 3.3. Baxter Healthcare Corp.
  • 3.3.1. Overview
  • 3.3.2. Financial Analysis
  • 3.3.3. SWOT Analysis
  • 3.3.4. Recent Developments
• 3.4. Cellectar Biosciences, INC.
  • 3.4.1. Overview
  • 3.4.2. Financial Analysis
  • 3.4.3. SWOT Analysis
  • 3.4.4. Recent Developments
• 3.5. United Therapeutics Corp.
  • 3.5.1. Overview
  • 3.5.2. Financial Analysis
  • 3.5.3. SWOT Analysis
  • 3.5.4. Recent Developments
• 3.6. Key Strategy Analysis

4. Market Segmentation

• 4.1. Global Pediatric Neuroblastoma Treatment Market by Treatment Type
  • 4.1.1. Chemotherapy
  • 4.1.2. Immunotherapy
  • 4.1.3. Radiation Therapy
  • 4.1.4. Others (Surgery, Targeted Therapy)
• 4.2. Global Pediatric Neuroblastoma Treatment Market by End-User
  • 4.2.1. Hospitals
  • 4.2.2. Specialty Clinics
  • 4.2.3. Others (Research Institutes)

5. Regional Analysis

• 5.1. North America
  • 5.1.1. United States
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. South Korea
  • 5.3.5. Rest of Asia-Pacific
• 5.4. Rest of the World

6. Company Profiles

• 6.1. AstraZeneca
• 6.2. Bayer AG
• 6.3. Bristol-Myers Squibb Co.
• 6.4. Cell Ectar Biosciences Inc.
• 6.5. Clarity Pharmaceuticals
• 6.6. Eli Lilly and Company
• 6.7. F. Hoffmann-La Roche AG
• 6.8. Johnson & Johnson Services, Inc.
• 6.9. MacroGenics Inc.
• 6.10. Marsala Biotech Inc.
• 6.11. Merck & Co.
• 6.12. Pfizer Inc.
• 6.13. Provectus Biopharmaceuticals Inc.
• 6.14. Sartorius AG
• 6.15. Sun Pharmaceuticals Industries Ltd.
• 6.16. Teva Pharmaceutical Industries Ltd.
• 6.17. Y-mAbs Therapeutics Inc.